

Review of interleukin-6 polymorphisms in rheumatoid arthritis: a genetic implications

Dhulfiqar Nidhal Alhilali¹, Samer Imad Mohammed^{1*}, Faiq Isho Gorial²

¹Department of Clinical Pharmacy, College of Pharmacy, University of Baghdad, Baghdad, Iraq. ²College of Medicine, University of Baghdad, Baghdad, Iraq.

Correspondence: Samer Imad Mohammed, Department of Clinical Pharmacy, College of Pharmacy, University of Baghdad, Baghdad, Iraq. samer.jameel@copharm.uobaghdad.edu.iq

ABSTRACT

The objective review is to inspect the involvement of Interleukin-6 (IL-6) in rheumatoid arthritis (RA) and to highlight the role of IL-6 and its variants in the pathogenesis of RA and response to anti-IL-6 agents. Several genetic and environmental risk factors and infectious agents contributed to the development of RA. Interleukin-6 is engaged in self-targeted immunity by modifying the equilibrium between T regulatory (T_{reg}) and T helper-17 (T_H-17) cells. The evidences reported that IL-6 participated in RA pathogenies including synovitis, angiogenesis, joint damage, and dislocations of bone. IL-6 induces peripheral and central pain sensitization that provokes chronic pain development. Many IL-6 loci contribute to the risk of RA development. Several IL-6 gene variants were studied, which included; -174, -572, -597, and -622 in the 5-flanking region (Promotor). The current data demonstrates the significant role of IL-6 promoter Single Nucleotide Polymorphisms (SNPs), particularly G (-174) C, in the susceptibility and pathogenesis of RA. The C allele linked with the risk, the genotypic and allelic frequencies were higher in Asian and Indian RA patients. Elevated serum IL-6 levels are observed in mutant homozygote CC carriers at the -174 locus, which could explain the impact of this SNP on RA. It seems that age, ethnicity, geographic region, and lifestyle impact the effect of the IL-6 variant in RA. In conclusion; because IL-6 plays a central role in the pathogenesis of RA and its symptoms, it can be speculated that IL-6 promoter SNP (rs1800795) could be a risk agent for RA.

Keywords: Rheumatoid arthritis, Interleukin-6, Genetics, Polymorphism, Pharmacogenetics

Introduction

Rheumatoid arthritis is a generalized autoimmune and chronic inflammatory disorder. Various organs and tissues could be affected, with the synovium of the joints being particularly impacted [1]. Rheumatoid arthritis affects approximately 0.5-1% of the global population, including 0.8% in the UK, the chronic synovial inflammation from RA can result in joint destruction and disability [2]. Several factors contribute to RA; including genetics, environmental influences, and autoimmunity, all of

which can lead to synovitis and the progression of RA [3]. Additionally, gender (male), age, and other chronic diseases correlated with the disease activity score [4].

Although the onset and progression of RA remain unclear, many therapeutic strategies are available. Rheumatoid arthritis is initially triggered by synovitis, where inflammatory cells such as lymphocytes and macrophages infiltrate the synovium [5]. This is followed by angiogenesis and synovial hyperplasia, along with excessive production of synovial fluid, leading to joint swelling accompanied by stiffness and pain [6]. Consequently, the articular cartilage in the joint becomes damaged, leading to bone erosion, osteoporosis, and, in some patients, eventual permanent disability [7].

Chronic inflammation in RA can lead to various systemic and general symptoms in patients, including anorexia, anemia, weight loss, fatigue, muscle weakness, fever, and cardiovascular disease [8]. Nowadays, the primary goals of therapeutic strategies are to reduce symptoms and relieve pain in RA patients, as well as to alternate the disease progress [9]. Many cytokines

Access this article online

Website: www.japer.in

E-ISSN: 2249-3379

How to cite this article: Alhilali DN, Mohammed SI, Gorial FI. Review of interleukin-6 polymorphisms in rheumatoid arthritis: a genetic implications. J Adv Pharm Educ Res. 2025;15(1):69-77. <https://doi.org/10.51847/bxjUqUoEla>

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-Non Commercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

(inflammatory mediators) like IL-6 play a significant role in the development of RA. Excessive production of IL-6 in the blood and synovial fluid has been observed in RA patients and is correlated with the disease pathogenesis [10]. IL-6 stimulates the production of auto-antibodies such as Rheumatoid Factor (RF), which then triggers several intra-articular events, including synovial inflammation, bone and cartilage damage, as well as extra-articular manifestations [11].

Several soluble anti-IL-6 agents and TNF- α inhibitors, such as tocilizumab and etanercept, work to slow the progression of rheumatoid arthritis (RA) by blocking IL-6 and TNF- α activity, respectively [12, 13]. This review aims to present current evidence on the genetic role in rheumatoid arthritis (RA), the pathological role of IL-6 in RA development, and the association between variants in the IL-6 gene and the incidence, development of RA, and response to therapy.

Data collection and examination

A systematic review was conducted to investigate the interplay between RA incidence, IL-6 signaling pathway, and genetic polymorphisms of IL-6. A comprehensive search strategy utilizing the keywords "RA," "genetic polymorphism," "IL-6," "IL-6 receptors," and "biological effect" was employed across Scopus, Google Scholar, PubMed, and Research databases. Eligible articles published between 2010 and December 2024 meeting pre-defined criteria were thoroughly examined and incorporated into this review.

The biology of IL-6

Interleukin-6 is a major multifunctional pro-inflammatory cytokine, that is involved in the immune response process, hematopoiesis, and inflammation [14].

Interleukin -6 is part of a broad cytokine family that includes many pro-inflammatory agents, like Cardiotrophin-like Cytokine Factor 1, Neurotrophic factor, Oncostatin, Leukaemia Inhibitory Factor Cardiotrophin and IL family (L-11, IL-27, IL-31 [15].

It has several pro-inflammatory characteristics, including promoting chemokine production and lymphocyte adhesion molecules. Additionally, during inflammation, IL-6 plays a crucial role in neutrophilia and granulocytic cell migration [16], it also has a principal role in both adaptive and innate immunity. It also plays an endocrine role by regulating the secreting state of the hypothalamus-pituitary-adrenal axis, while also increasing cortisol and adrenocorticotrophic hormone levels [17].

The types of inflammation and the infection could induce IL-6 production [18]. In fact, IL-6 is produced principally by macrophages in response to inflammation or pathogenic agents. It exerts a protective activity by eliminating infectious causes and repairing damaged tissues through stimulation of immune responses and activation of acute phase pathways [19]. At sites of inflammation, many cell types contribute to IL-6 production such as T-lymphocytes, monocytes, endothelial cells, and fibroblasts [20].

Interleukin-6 impacts both the acquired and innate immunity. At the site of inflammation, IL-6 acts as a chemoattractant by stimulating the infiltration of mononuclear cells and the neutrophils migration, while also serving as a chemoreceptor for monocytes [17].

Impact of IL-6 on the pathogenesis of RA

The exact cause of RA remains unclear, it has been proven that IL-6 contributes to the onset and progress of the disease. The clinical analysis showed that higher IL-6 levels were noticed in the blood and synovial fluid of RA patients [10], they inferred that related to the disease activity. Although many factors could impact RA pathogenesis, several studies pointed out that there is a correlation between the IL-6 blood level and RA [18]. However, the sIL-6R expression level in the blood does not differ between RA patients and healthy individuals. On the opposite, the upregulation of sIL-6R is observed in the synovial fluid of RA patients compared to OA patients [19]. The lymphocytes and monocytes that infiltrate into synovial fluid are considered the origin of sIL-6R [20].

• *Roles of IL-6 in synovitis*

The synovitis is maintained and supported by the inflammatory cells' infiltration from the newly formed blood vessels and the growing synovial cells. Many cytokines and growth factors are involved in RA pathogenesis; however, the Vascular Endothelial Growth Factor (VEGF) is the primary factor due to its angiogenic activity [21]. The VEGF plays a specific role in the pathogenesis of RA, particularly in the formation of inflammatory vascular tissue (pannus). There is a significant rise in VEGF circulatory concentration in RA patients [22]. Additionally, clinical trials have shown that anti-VEGF antibodies suppress IL-6-induced angiogenesis by preventing IL-6 from inducing Fibroblast-Like Synoviocytes (FLS) in RA patients [23].

Furthermore, IL-6 improved the Monocyte Chemotactic Protein-1 and FLS production and increased monocyte adhesion to endothelial cells by stimulating the production of endothelial adhesion molecules (ICAM) like ICAM-1 [24].

Large amounts of IL-6 are expressed by synovial fibroblastic cells through TAK1/NF- κ B/HIF-1 α signaling in response to some pro-inflammatory mediators such as IL-1, IL-17, and TNF α that finally IL-6 amplified synovial fibroblastic cells [25]. Some IL-6R inhibitors inhibit the biological activities of IL-6 and significantly improve synovitis in RA patients [26].

• *Impact of IL-6 in joint damage*

Irreversible joint damage, dislocations, and bone disintegration is a distinctive trait of RA. The Pro-inflammatory cytokines activate osteoclasts, resulting in localized bone erosion and subsequent destruction [27].

The internal layer lining the bone marrow, which contains FLS-A and FLS-B, contributes to tissue damage. FLS-A and FLS-B primarily produce TNF, IL-6, and other cytokines [28]. Local

arthritic signs arise from the combined effects of TNF, IL-6, and cytokines derived from FLS [29].

Both osteoblasts and osteoclasts expressed IL-6R [30], therefore, IL-6 is considered a potential mediator of osteoclast function which triggers the immune response and exacerbates the deterioration of RA [31].

In RA patients, osteoclasts have been determined at the cartilage destruction sites [27]. Additionally, IL-6 and IL-6R increase bone resorption; the IL-6/sIL-6R ligand straightaway stimulates osteoclastogenesis [32]. Interleukin-6 regulates the inflammatory process by promoting pannus development and bone resorption through osteoclast activity. This leads to the autoimmune production of antibodies (IgM and IgG), RFs, and citrullinated peptides (dysregulated citrullination) [32].

Additionally, clinical evidence has shown that IL-6 signaling affects bone resorption and osteoclastogenesis, blocking osteoclast activity occurs directly through the use of an IL-6R inhibitor [33].

Furthermore, by influencing TNF α and IL-1, IL-6 mediates bone resorption inflammation and thickening of the synovial membranes, which is accompanied by cartilage, bone erosion, and pannus formation [34]. These events occur due to IL-6 stimulates neutrophils infiltration into the joint, promotes angiogenesis, and alters the differentiation of both B and T cells [35], as well as, stimulation of Matrix metalloproteinase (MMP)-1, 3, and 13 from synovial cells and chondrocytes [36].

Moreover, the synthesized IL-6 that originates from the inflamed joint reaches the liver through systemic circulation, which in turn stimulates adaptive immunity by prompting hepatocytes to secrete serum Amyloid A, Fibrinogen, and C-reactive Protein (CRP). These mediators contribute to the persistence of chronic inflammation and joint disruption [37].

Genetic contribution to RA

Several autoimmune disorders are influenced by hereditary [38-41]. The hereditary potential of RA has been assessed between 50 to 60 % [38]. The risk of developing RA increases approximately 3 to 5 times in families with a history of the disease [38]. Genetic factors such as Major Histocompatibility Antigens (class II), Human Leukocyte Antigens (HLA), and non-HLA genes have been involved in the pathogenesis of RA [42, 43].

Many studies find a linkage between the SNPs with certain loci and RA. Large-scale cohort studies have permitted the simultaneous estimate of dozens of genes, leading to a comprehensive finding of genetic relevance [44]. For instance, certain genes are associated with some disease's development and/or prognosis [45-50]. While some gene screening is related to nonresponse or response to treatment, and also to the degree of response (good or bad) to therapy [51]. In Iraq, numerous recent reviews and studies have reported on genetics, including genetic SNPs in various genes like TNF and ILs, which influence the response of RA patients to biological therapies such as Adalimumab and Etanercept [52-56].

Based upon the clinical trials on animal models for RA, both B and T immune cells participated because it contributed directly

to the risk and pathogenesis of this disease particularly in the inflammation synovial joint [57].

About 31 confirmed genetic loci in non-HLA genes contributing to RA risk, the loci of PTPN22 and IL23R genes demonstrated a strong association with RA [58]. Farago *et al.* (2009) [59] also the outcomes demonstrated a linkage of some gene's loci with RA in Hungarian RA patients.

For instance, because the peptidyl arginine-deiminase 4 (PADI4) enzyme that encodes with the PADI4 gene has a main role in the information of protein citrullination, it participates in RA pathogenesis of RA [60]. The PADI4 haplotype correlation with RA was speculated in Asian populations but could not be verified in Caucasian population cohorts [61] and a lack of association was recorded in European patients [62]. Other important genetic loci include TRAF1, CD40, FCGR2A, TNF- α , IL-4, and IL2RA/IL2RB genes have been the most powerful correlation [63-67].

It has been shown that several distinct HLA alleles (called HLA-DRB1*01) correlated with RA susceptibility [68]. Some alleles in HLADRB1 can stimulate citrullinated protein through particular T cell reactions by the presence of citrulline in its own antigens anchoring pockets [69]. Often, HLA-DRB1 alleles are intensely connected with the anti-citrullinated protein antibodies seropositive RA [70]. It also confirmed that genetic loci in this gene were relevant with RF and anti-citrullinated protein antibodies seropositive-RA group along with RA severity and bad prognosis [71].

IL-6 polymorphisms and RA

Several IL-6 gene variants were studied and determined the association with RA including four located at positions -174 (rs1800795), -572 (rs1800796), -597, and - 622 in the 5-flanking region [72].

Ren *et al.* (2023) [72] first recorded the G>C SNP in the 5-untranslated region (flanking region) at a locus (174G > C) (promotor region), it made the G to C substitution and could make in-vitro changes in transcriptional reaction to the stimuli of HeLa cells. The connection between the IL-6 variant (174 G>C) and the risk of RA susceptibility was studied; Shafia *et al.* (2014) [73] studied the IL-6-174 SNP in the north Indian population; they reported that G allele frequency was 82.5% in the patient cohorts in comparison to the control group 90%, In contrast, C allele was recorded 17.5% compared to 10% in the same group. Additionally, a significant variance was reported in the genotypic frequency of CC (10% Vs 0%) and GG (75% Vs 80%) in both RA patient and control groups. Hence, it can be concluded that the IL-6-174 locus is strongly related to RA susceptibility in north Indian cohorts. Subgroup analysis also detected that the IL-6-174 G>C locus demonstrated a significant connection with the susceptibility to RA in the Asian population [74]. While the case-control studies that have been done on Caucasian RA patients did not show a significant correlation between the allelic distributions of IL-6-174G>C variant and the risk of developing RA [75-77].

For Middle Eastern countries, there is a potential heterogeneity for all the genetic prototypes; The heterozygous, dominant, allelic genetic models and increase the risk to RA exhibited a significant correlation for the -174 locus [78, 79]. While the -572 variant did not demonstrate a degree of significance for heterogeneity except in Asian people carriers. Additionally, the susceptibility and risk of RA development increased in the CC genotype (C allele) [80, 81]. Unexpectedly, the -174 polymorphism was related to some benefits, it correlated with some protective impact for Latin populations [82].

Although, the -597 SNP is not responsible for developing RA; however, the -572 polymorphism could raise the risk of susceptibility to RA, particularly in Middle Eastern and Asian populations [78, 79].

Several pieces of evidence reported the effect of IL-6 -174 polymorphism on IL-6 plasma concentration. Some clinical trials explained the effect of the variant on IL-6; In vivo, the serum levels of IL-6 elevated among RA patients with IL-6 -174 mutant homozygote allele (CC genotype) and also in heterozygote GC genotypes than that with wild homozygote allele (GG genotype), therefore, it has been related with elevation of IL-6 levels [83] in the general population. Another study finds that there is a significant increase in the circulatory IL-6 level in RA patients that have wild allele and genotypes (GG+GC genotypes) in comparison with the mutant homozygote CC carriers [84].

The existence of repetitive inflammatory stimulants in RA patients may be correlated with a more significantly impact of the -174C allele on IL-6 blood concentrations in the serum and synovial fluid, in this context, the high IL6 concentrations in the C allele patients could be deteriorated the RA consequences and raised prevalence of cardiovascular disease in RA patients by triggering and intensified the inflammation condition [85].

Since the IL-6 variant is effected by many confounding factors; It has shown that IL-6 level is also influenced by circadian rhythm, stress, diet regime, adipose tissue density (obesity), smoking and elderly considered an additional triggering agent for IL-6 formation and rising plasma IL-6 levels in the RA patients that possess -174C allele [86, 87]. Although it seems that the promoter SNP tended to rise of IL-6 production [88], the prevalence and effect of this variant were significantly geographic and ethnicity different and with significant heterogeneity in the genetic models.

It is possible that age also impacts in the effect of IL-6 variant in RA; there is a statistical difference ($P < 0.05$) in average ages of healthy controls and RA patients (47 Vs 50 years), the finding concluded that age and IL-6 gene SNP-RA have a risk connection [89].

Based on ethnicity, Li *et al.* (2016) [79] reported that the dominant homozygous IL-6-174 C allele is significantly related with 4.5-fold, 1.8-fold and 4.7-fold raised the susceptibility of RA in Asian RA carriers for IL6-174 C allele, while, under three genetic models; there is non-significant relation was recorded in Europeans RA patients.

The statistical distribution according to the geographic region that the significant differences only appeared in eastern China RA patients, additionally, the risk of RA was significantly rise in

people that have -174C allele [90]. The genotype distributions showed that these Asian populations and Middle Eastern carriers had the minimum allelic frequencies (1-10%) [72, 73]. In contrast, it was higher in European carriers (40%) [91, 92]. As the G allele is connected with lower serum IL-6 concentration [92], they inferred that a majority of Europeans have a minor circulatory IL-6 concentration.

The quality of life and lifestyle choices play a significant role in modulating the impact of the -174 variant on the progression of rheumatoid arthritis (RA). An unhealthy lifestyle, particularly one characterized by a diet rich in unhealthy carbohydrates, can elevate circulatory levels of interleukin-6 (IL-6), thereby exacerbating inflammatory responses and contributing to the development and progression of RA [93]. This suggests that poor dietary habits may enhance the responsiveness of the immune system to inflammatory conditions, leading to increased IL-6 levels and a heightened risk of RA. Indeed, autoimmune diseases such as RA are influenced by genetic polymorphisms, including those affecting cytokine regulation [94]. Among these cytokines, IL-6 is particularly notable due to its central role in inflammatory processes and its association with disease severity. Thus, both genetic factors and lifestyle choices interact to shape the immune response and influence the course of autoimmune conditions like RA.

Conclusion

In summary, the data revealed that IL-6 influences the pathogenesis of RA and in its symptoms, it can be inferred that IL-6 promoter SNP (rs1800795) could be a genetic predisposing factor for RA. The relationship between IL-6 SNPs could assist physicians in identifying individuals at higher risk for developing RA in the future and in predicting their response to RA treatment.

Acknowledgments: We are also thankful to the head of the clinical pharmacy department for the critical feedback and thoughtful insights, which have significantly improved the quality of this manuscript.

Conflict of interest: None

Financial support: None

Ethics statement: None

References

1. Cross M, Smith E, Hoy D, Carmona L, Wolfe F, Vos T, et al. The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study. *Ann Rheum Dis.* 2014;73(7):1316-22. doi:10.1136/annrheumdis-2013-204627
2. Wu Q, Wang H, Wu Y, Tao L, Wang W, Yin S, et al. The burden of rheumatoid arthritis in China from 1990-2021:

- an analysis based on the global burden of disease study 2021. 2024;1-23.
3. Choi MY, Costenbader KH, Fritzler MJ. Environment and systemic autoimmune rheumatic diseases: an overview and future directions. *Front Immunol.* 2024;15:1456145. doi:10.3389/fimmu.2024.1456145
 4. Faiq MK, Kadhim DJ, Gorial FI. The belief about medicines among a sample of Iraqi patients with rheumatoid arthritis. *Iraqi J Pharm Sci.* 2019;28(2):134-41. doi:10.31351/vol28iss2pp134-141
 5. Bricman L, Triaille C, Sapart E, Sokolova T, Avramovska A, Natalucci F, et al. Analysis of synovitis patterns in early RA supports the importance of joint-specific factors. *Semin Arthritis Rheum.* 2024;68:152524. doi:10.1016/j.semarthrit.2024.152524
 6. Kerekes G, Czókolyová M, Hamar A, Pusztai A, Tajti G, Katkó M, et al. Effects of 1-year tofacitinib therapy on angiogenic biomarkers in rheumatoid arthritis. *Rheumatology (Oxford).* 2023;62(SI3):SI304-12. doi:10.1093/rheumatology/kead502
 7. Gong X, Xu SQ, Tong H, Wang XR, Zong HX, Pan MJ, et al. Correlation between systemic osteoporosis and local bone erosion with rheumatoid arthritis patients in Chinese population. *Rheumatology (Oxford).* 2019;58(8):1443-52. doi:10.1093/rheumatology/kez042
 8. Allen A, Carville S, McKenna F; Guideline Development Group. Diagnosis and management of rheumatoid arthritis in adults: summary of updated NICE guidance. *BMJ.* 2018;362:k3015. doi:10.1136/bmj.k3015
 9. Taylor PC, Alten R, Álvaro Gracia JM, Kaneko Y, Walls C, Quebe A, et al. Achieving pain control in early rheumatoid arthritis with baricitinib monotherapy or in combination with methotrexate versus methotrexate monotherapy. *RMD Open.* 2022;8(1):e001994. doi:10.1136/rmdopen-2021-001994
 10. Shaik MB, Vurundhur D, Mallam KK, Gulabi M. Analysis of IL-6 marker in synovial fluid of the knee joint in patients with osteoarthritis and rheumatoid arthritis before and after platelet-rich plasma administration. *J Res Appl Basic Med Sci.* 2024;10(1):80-7. doi:10.61186/rabms.10.1.80
 11. Fang Q, Zhou C, Nandakumar KS. Molecular and cellular pathways contributing to joint damage in rheumatoid arthritis. *Mediators Inflamm.* 2020;2020(1):3830212. doi:10.1155/2020/3830212
 12. Hussain SA, Abood SJ, Gorial FI. The adjuvant use of calcium fructoborate and borax with etanercept in patients with rheumatoid arthritis: pilot study. *J Intercult Ethnopharmacol.* 2016;6(1):58-64. doi:10.5455/jice.20161204021549
 13. Alotaibi AM, Albahdal AS, Abanmy N, Alwhaibi M, Asiri Y, AlRuthia Y. Health-related quality of life of patients with rheumatoid arthritis on tocilizumab, adalimumab, and etanercept in Saudi Arabia: a single-center cross-sectional study. *Front Pharmacol.* 2023;14:1299630. doi:10.3389/fphar.2023.1299630
 14. Zeb S, Khan Z, Javaid M, Swati MA, Javaid Z, Luqman M. Relationship between serum Interleukin-6 levels, systemic immune-inflammation index, and other biomarkers across different rheumatoid arthritis severity levels. *Cureus.* 2024;16(10):e72334. doi:10.7759/cureus.72334
 15. Kang S, Narazaki M, Metwally H, Kishimoto T. Historical overview of the interleukin-6 family cytokine. *J Exp Med.* 2020;217(5):e20190347. doi:10.1084/jem.20190347
 16. Zegeye MM, Matic L, Lengquist M, Hayderi A, Grenegård M, Hedin U, et al. Interleukin-6 trans-signaling induced laminin switch contributes to reduced trans-endothelial migration of granulocytic cells. *Atherosclerosis.* 2023;371:41-53. doi:10.1016/j.atherosclerosis.2023.03.010
 17. Zarković M, Ignjatović S, Dajak M, Cirić J, Beleslin B, Savić S, et al. Cortisol response to ACTH stimulation correlates with blood interleukin 6 concentration in healthy humans. *Eur J Endocrinol.* 2008;159(5):649-52. doi:10.1530/EJE-08-0544
 18. Conti P, Ronconi G, Caraffa A, Gallenga CE, Ross R, Frydas I, et al. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. *J Biol Regul Homeost Agents.* 2020;34(2):327-31. doi:10.23812/CONTI-E
 19. Pandolfi F, Altamura S, Frosali S, Conti P. Key role of DAMP in inflammation, cancer, and tissue repair. *Clin Ther.* 2016;38(5):1017-28. doi:10.1016/j.clinthera.2016.02.028
 20. Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. *Nat Immunol.* 2015;16(5):448-57. doi:10.1038/ni.3153
 21. Baillet A, Gossec L, Paternotte S, Etcheto A, Combe B, Meyer O, et al. Evaluation of serum interleukin-6 level as a surrogate marker of synovial inflammation and as a factor of structural progression in early rheumatoid arthritis: results from a French national multicenter cohort. *Arthritis Care Res (Hoboken).* 2015;67(7):905-12. doi:10.1002/acr.22513
 22. Kotake S, Sato K, Kim KJ, Takahashi N, Udagawa N, Nakamura I, et al. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. *J Bone Miner Res.* 1996;11(1):88-95. doi:10.1002/jbmr.5650110113
 23. Nowell MA, Richards PJ, Horiuchi S, Yamamoto N, Rose-John S, Topley N, et al. Soluble IL-6 receptor governs IL-6 activity in experimental arthritis: blockade of arthritis severity by soluble glycoprotein 130. *J Immunol.* 2003;171(6):3202-9. doi:10.4049/jimmunol.171.6.3202
 24. Zhang N, Zheng N, Luo D, Lin J, Lin D, Lu Y, et al. A novel single domain bispecific antibody targeting VEGF and TNF- α ameliorates rheumatoid arthritis. *Int Immunopharmacol.* 2024;126:111240. doi:10.1016/j.intimp.2023.111240

25. Lee YH, Bae SC. Correlation between circulating VEGF levels and disease activity in rheumatoid arthritis: a meta-analysis. *Z Rheumatol.* 2018;77(3):240-8. doi:10.1007/s00393-016-0229-5
26. Hashizume M, Hayakawa N, Suzuki M, Mihara M. IL-6/sIL-6R trans-signalling, but not TNF-alpha induced angiogenesis in a HUVEC and synovial cell co-culture system. *Rheumatol Int.* 2009;29(12):1449-54. doi:10.1007/s00296-009-0885-8
27. Suzuki M, Hashizume M, Yoshida H, Shiina M, Mihara M. IL-6 and IL-1 synergistically enhanced the production of MMPs from synovial cells by up-regulating IL-6 production and IL-1 receptor I expression. *Cytokine.* 2010;51(2):178-83. doi:10.1016/j.cyto.2010.03.017
28. Wang G, Wang J, Li X, Wu Q, Yao R, Luo X. Hypoxia and TNF- α synergistically induce expression of IL-6 and IL-8 in human fibroblast-like synoviocytes via enhancing TAK1/NF- κ B/HIF-1 α signaling. *Inflammation.* 2023;46(3):912-24. doi:10.1007/s10753-022-01779-x
29. Yoshida H, Magi M, Tamai H, Kikuchi J, Yoshimoto K, Otomo K, et al. Effects of interleukin-6 signal inhibition on treg subpopulations and association of tregs with clinical outcomes in rheumatoid arthritis. *Rheumatology (Oxford).* 2024;63(9):2515-24. doi:10.1093/rheumatology/keae196
30. Stojanovic SK, Stamenkovic BN, Cvetkovic JM, Zivkovic VG, Apostolovic MRA. Matrix metalloproteinase-9 level in synovial fluid-association with joint destruction in early rheumatoid arthritis. *Medicina (Kaunas).* 2023;59(1):167. doi:10.3390/medicina59010167
31. Yuan X, Luo F, Li C, Hong X, Ma W, Yao X. Multiple joint dislocations and bone disintegration in rheumatoid arthritis: a case report. *Int J Rheum Dis.* 2023;26(5):946-9. doi:10.1111/1756-185X.14549
32. Niu Q, Gao J, Wang L, Liu J, Zhang L. Regulation of differentiation and generation of osteoclasts in rheumatoid arthritis. *Front Immunol.* 2022;13:1034050. doi:10.3389/fimmu.2022.1034050
33. Ganesan R, Rasool M. Fibroblast-like synoviocytes-dependent effector molecules as a critical mediator for rheumatoid arthritis: current status and future directions. *Int Rev Immunol.* 2017;36(1):20-30. doi:10.1080/08830185.2016.1269175
34. Melo RCO, Martins AA, Vieira GHA, Andrade RVS, Silva DNA, Chalmers J, et al. Selective inhibition of interleukin 6 receptor decreased inflammatory cytokines and increased proteases in an experimental model of critical calvarial defect. *Braz J Med Biol Res.* 2024;57:e13913. doi:10.1590/1414-431X2024e13913
35. Yokota K, Sato K, Miyazaki T, Aizaki Y, Tanaka S, Sekikawa M, et al. Characterization and function of tumor necrosis factor and interleukin-6-induced osteoclasts in rheumatoid arthritis. *Arthritis Rheumatol.* 2021;73(7):1145-54. doi:10.1002/art.41666
36. Hashizume M, Mihara M. The roles of interleukin-6 in the pathogenesis of rheumatoid arthritis. *Arthritis.* 2011;2011:765624. doi:10.1155/2011/765624
37. Darrah E, Andrade F. Rheumatoid arthritis and citrullination. *Curr Opin Rheumatol.* 2018;30(1):72-8. doi:10.1097/BOR.0000000000000452
38. Axmann R, Böhm C, Krönke G, Zwerina J, Smolen J, Schett G. Inhibition of interleukin-6 receptor directly blocks osteoclast formation in vitro and in vivo. *Arthritis Rheum.* 2009;60(9):2747-56. doi:10.1002/art.24781
39. Valin A, Del Rey MJ, Municio C, Usategui A, Romero M, Fernández-Felipe J, et al. IL6/sIL6R regulates TNF α -inflammatory response in synovial fibroblasts through modulation of transcriptional and post-transcriptional mechanisms. *BMC Mol Cell Biol.* 2020;21(1):74. doi:10.1186/s12860-020-00317-7
40. McInnes IB, Buckley CD, Isaacs JD. Cytokines in rheumatoid arthritis - shaping the immunological landscape. *Nat Rev Rheumatol.* 2016;12(1):63-8. doi:10.1038/nrrheum.2015.171
41. Mukherjee A, Das B. The role of inflammatory mediators and matrix metalloproteinases (MMPs) in the progression of osteoarthritis. *Biomater Biosyst.* 2024;13:100090. doi:10.1016/j.bbiosy.2024.100090
42. Warjekar PR, Mohabey AV, Jain PB, Bandre GR. Decoding the correlation between inflammatory response marker interleukin-6 (IL-6) and C-reactive protein (CRP) with disease activity in rheumatoid arthritis. *Cureus.* 2024;16(6):e62954. doi:10.7759/cureus.62954
43. Stahl EA, Raychaudhuri S, Remmers EF, Xie G, Eyre S, Thomson BP, et al. Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. *Nat Genet.* 2010;42(6):508-14. doi:10.1038/ng.582
44. Ahmed FT, Ali SH, Al Gawwam GA. Integrin alpha-4 gene polymorphism in relation to natalizumab response in multiple sclerosis patients. *Neurol Asia.* 2023;28(2):349-58. doi:10.54029/2023afn
45. Ahmed FT, Ali SH, AL Gawwam GA. Correlation between integrin Alpha-4 gene polymorphisms and failure to respond to natalizumab therapy in Iraqi multiple sclerosis patients. *Farmacia.* 2023;71(3):563-72. doi:10.31925/farmacia.2023.3.15
46. de Vries R. Genetics of rheumatoid arthritis: time for a change! *Curr Opin Rheumatol.* 2011;23(3):227-32. doi:10.1097/BOR.0b013e3283457524
47. Curran AM, Girgis AA, Jang Y, Crawford JD, Thomas MA, Kawalerski R, et al. Citrullination modulates antigen processing and presentation by revealing cryptic epitopes in rheumatoid arthritis. *Nat Commun.* 2023;14(1):1061. doi:10.1038/s41467-023-36620-y
48. Wellcome Trust Case Control Consortium; Craddock N, Hurles ME, Cardin N, Pearson RD, Plagnol V, et al. Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. *Nature.* 2010;464(7289):713-20. doi:10.1038/nature08979

49. Jiang Y, Zhong S, He S, Weng J, Liu L, Ye Y, et al. Biomarkers (mRNAs and non-coding RNAs) for the diagnosis and prognosis of rheumatoid arthritis. *Front Immunol.* 2023;14:1087925. doi:10.3389/fimmu.2023.1087925
50. Cao G, Luo Q, Wu Y, Chen G. Inflammatory bowel disease and rheumatoid arthritis share a common genetic structure. *Front Immunol.* 2024;15:1359857. doi:10.3389/fimmu.2024.1359857
51. Leipe J, Schramm MA, Prots I, Schulze-Koops H, Skapenko A. Increased Th17 cell frequency and poor clinical outcome in rheumatoid arthritis are associated with a genetic variant in the IL4R gene, rs1805010. *Arthritis Rheumatol.* 2014;66(5):1165-75. doi:10.1002/art.38343
52. Mohammed SI, Zalzal MH, Gorial FI. The effect of TNF-alpha gene polymorphisms at-376 G/A, -806 C/T, and-1031 T/C on the likelihood of becoming a non-responder to etanercept in a sample of Iraqi rheumatoid arthritis patients. *Iraqi J Pharm Sci.* 2022;31(2):113-28. doi:10.31351/vol31iss2pp113-128
53. Mohammed S, Zalzal M, Gorial F. Association of tumor necrosis factor-alpha promoter region gene polymorphism at positions -308G/A, -857C/T, and -863C/A with etanercept response in Iraqi rheumatoid arthritis patients. *Arch Rheumatol.* 2022;37(4):613-25. doi:10.46497/ArchRheumatol.2022.9272
54. Mohammed SI, Jasim AL, Jamal MY, Hussain SA. Factors influencing adalimumab treatment response in patients with rheumatoid arthritis: the future of clinical expertise. *Al-Rafidain J Med Sci.* 2023;5:192-204. doi:10.54133/ajms.v5i.232
55. Mohammed SI, Jamal MY, Alshamari IO. The association of genetic polymorphisms in tumor necrosis factor-alpha and interleukins with disease severity or response to biological therapy in Iraqi rheumatoid arthritis patients: a narrative review. *Al-Rafidain J Med Sci.* 2023;4:24-33. doi:10.54133/ajms.v4i.100
56. Mohammed SI, Zalzal MH, Gorial FI. Association between genetic polymorphism in tumor necrosis factor-alpha gene and adverse effects of etanercept in rheumatoid arthritis patients. *Rom J Rheumatol.* 2023;32(3):104-10. doi:10.37897/RJR.2023.3.3
57. de Jong TA, de Hair MJH, van de Sande MGH, Semmelink JF, Choi IY, Gerlag DM, et al. Synovial gene signatures associated with the development of rheumatoid arthritis in at risk individuals: a prospective study. *J Autoimmun.* 2022;133:102923. doi:10.1016/j.jaut.2022.102923
58. Shaik NA, Banaganapalli B. Computational molecular phenotypic analysis of PTPN22 (W620R), IL6R (D358A), and TYK2 (P1104A) gene mutations of rheumatoid arthritis. *Front Genet.* 2019;10:168. doi:10.3389/fgene.2019.00168
59. Farago B, Talian GC, Komlosi K, Nagy G, Berki T, Gyetvai A, et al. Protein tyrosine phosphatase gene C1858T allele confers risk for rheumatoid arthritis in Hungarian subjects. *Rheumatol Int.* 2009;29(7):793-6. doi:10.1007/s00296-008-0771-9
60. Matuz-Flores MG, Rosas-Rodríguez JA, Tortoledo-Ortiz O, Muñoz-Barríos S, Martínez-Bonilla GE, Hernández-Bello J, et al. *PADI4* haplotypes contribute to mRNA expression, the enzymatic activity of peptidyl arginine deaminase and rheumatoid arthritis risk in patients from Western Mexico. *Curr Issues Mol Biol.* 2022;44(9):4268-81. doi:10.3390/cimb44090293
61. Poór G, Nagy ZB, Schmidt Z, Brózik M, Merétey K, Gergely P Jr. Genetic background of anticyclic citrullinated peptide autoantibody production in Hungarian patients with rheumatoid arthritis. *Ann N Y Acad Sci.* 2007;1110:23-32. doi:10.1196/annals.1423.004
62. Ciesla M, Kolarz B, Darmochwal-Kolarz D. The lack of association between *PADI4*₉₄ or *PADI4*₁₀₄ polymorphisms and RF, ACPA and anti-PAD4 in patients with rheumatoid arthritis. *Sci Rep.* 2022;12(1):11882. doi:10.1038/s41598-022-15726-1
63. Yang Y, Yuan S, Che M, Jing H, Yuan L, Dong K, et al. Genetic analysis of the relation between IL2RA/IL2RB and rheumatoid arthritis risk. *Mol Genet Genomic Med.* 2019;7(7):e00754. doi:10.1002/mgg3.754
64. Riaz N, Arshad M, Zubair F. Polymorphism in CD40 gene associated with the prevalence of rheumatoid arthritis in Pakistan. *Pakistan J Zool.* 2024;1-4. doi:10.17582/journal.pjz/20191230091215
65. Hashim Z. Genetic polymorphism in TNF- α promoter region: its association with severity and susceptibility to rheumatoid arthritis in Iraqi patients with active disease. *Iraqi J Pharm Sci.* 2023;32(2):46-57. doi:10.31351/vol32iss2pp46-57
66. Ravaci A, Pulsatelli L, Assirelli E, Ciaffi J, Meliconi R, Salvarani C, et al. *MTHFR* c.665C>T and c.1298A>C polymorphisms in tailoring personalized Anti-TNF- α therapy for rheumatoid arthritis. *Int J Mol Sci.* 2023;24(4):4110. doi:10.3390/ijms24044110
67. Inoue M, Nagafuchi Y, Ota M, Tsuchiya H, Tateishi S, Kanda H, et al. Carriers of HLA-DRB1*04:05 have a better clinical response to abatacept in rheumatoid arthritis. *Sci Rep.* 2023;13(1):15250. doi:10.1038/s41598-023-42324-6
68. van der Helm-van Mil AH, Verpoort KN, le Cessie S, Huizinga TW, de Vries RR, Toes RE. The HLA-DRB1 shared epitope alleles differ in the interaction with smoking and predisposition to antibodies to cyclic citrullinated peptide. *Arthritis Rheum.* 2007;56(2):425-32. doi:10.1002/art.22373
69. Scott IC, Steer S, Lewis CM, Cope AP. Precipitating and perpetuating factors of rheumatoid arthritis immunopathology: linking the triad of genetic predisposition, environmental risk factors and autoimmunity to disease pathogenesis. *Best Pract Res Clin Rheumatol.* 2011;25(4):447-68. doi:10.1016/j.berh.2011.10.010

70. de Rooy DP, Tsonaka R, Andersson ML, Forslind K, Zhernakova A, Frank-Bertoncelj M, et al. Genetic factors for the severity of ACPA-negative rheumatoid arthritis in 2 cohorts of early disease: a genome-wide study. *J Rheumatol.* 2015;42(8):1383-91. doi:10.3899/jrheum.140741
71. Arman A, Coker A, Sarioz O, Inanc N, Direskeneli H. Lack of association between IL-6 gene polymorphisms and rheumatoid arthritis in Turkish population. *Rheumatol Int.* 2012;32(7):2199-201. doi:10.1007/s00296-011-2057-x
72. Ren H, Guo Z, Qin WJ, Yang ZL. Association of interleukin-6 genetic polymorphisms (rs1800795, -174C > G and rs1800796, -572G > C) with risk of essential hypertension in the chinese population. *Cureus.* 2023;15(10):e46334. doi:10.7759/cureus.46334
73. Shafia S, Dilafoze, Sofi FA, Rasool R, Javeed S, Shah ZA. Rheumatoid arthritis and genetic variations in cytokine genes: a population-based study in Kashmir Valley. *Immunol Invest.* 2014;43(4):349-59. doi:10.3109/08820139.2013.879171
74. You CG, Li XJ, Li YM, Wang LP, Li FF, Guo XL, et al. Association analysis of single nucleotide polymorphisms of proinflammatory cytokine and their receptors genes with rheumatoid arthritis in northwest Chinese Han population. *Cytokine.* 2013;61(1):133-8. doi:10.1016/j.cyto.2012.09.007
75. Trajkov D, Mishevska-Perchinkova S, Karadzova-Stojanoska A, Petlichkovski A, Strezova A, Spiroski M. Association of 22 cytokine gene polymorphisms with rheumatoid arthritis in population of ethnic Macedonians. *Clin Rheumatol.* 2009;28(11):1291-300. doi:10.1007/s10067-009-1238-4
76. Emonts M, Hazes MJ, Houwing-Duistermaat JJ, van der Gaast-de Jongh CE, de Vogel L, Han HK, et al. Polymorphisms in genes controlling inflammation and tissue repair in rheumatoid arthritis: a case control study. *BMC Med Genet.* 2011;12:36. doi:10.1186/1471-2350-12-36
77. Dar SA, Haque S, Mandal RK, Singh T, Wahid M, Jawed A, et al. Interleukin-6-174G > C (rs1800795) polymorphism distribution and its association with rheumatoid arthritis: a case-control study and meta-analysis. *Autoimmunity.* 2017;50(3):158-69. doi:10.1080/08916934.2016.1261833
78. Ad'hiah AH, Mahmood AS, Al-kazaz AK, Mayouf KK. Gene expression and six single nucleotide polymorphisms of interleukin-6 in rheumatoid arthritis: a case-control study in Iraqi patients. *Alex J Med.* 2018;54(4):639-45. doi:10.1016/j.ajme.2018.08.001
79. Li B, Xiao Y, Xing D, Ma XL, Liu J. Circulating interleukin-6 and rheumatoid arthritis: a mendelian randomization meta-analysis. *Medicine (Baltimore).* 2016;95(23):e3855. doi:10.1097/MD.0000000000003855
80. Liu X, Xu J, Hu CD, Pan ZL, Zhang YC. The relationship between SNPs in the genes of TLR signal transduction pathway downstream elements and rheumatoid arthritis susceptibility. *Tsitol Genet.* 2014;48(3):24-9. doi:10.3103/S0095452714030074
81. Gomes-Silva II, Rushansky E, Carvalho-Neto FG, Vieira AV, de Araujo Mariano MH, de Souza PR, et al. The pattern of methylation and polymorphism in interleukin-6 promoter gene are related to the development of rheumatoid arthritis? *Acta Med Iran.* 2018;56(7):429-33.
82. Ahmed I. Association of IL-6 genotypes with their serum levels among Iraqi patients with rheumatoid arthritis. *Wasit J Pure Scie.* 2022;1(2):187-91. doi:10.31185/wjps.50
83. Jančić I, Arsenović-Ranin N, Sefik-Bukilica M, Zivojinović S, Damjanov N, Spasovski V, et al. -174G/C interleukin-6 gene promoter polymorphism predicts therapeutic response to etanercept in rheumatoid arthritis. *Rheumatol Int.* 2013;33(6):1481-6. doi:10.1007/s00296-012-2586-y
84. López-Mejías R, Castañeda S, González-Juanatey C, Corrales A, Ferraz-Amaro I, Genre F, et al. Cardiovascular risk assessment in patients with rheumatoid arthritis: the relevance of clinical, genetic and serological markers. *Autoimmun Rev.* 2016;15(11):1013-30. doi:10.1016/j.autrev.2016.07.026
85. Goletzke J, Buyken AE, Joslowski G, Bolzenius K, Remer T, Carstensen M, et al. Increased intake of carbohydrates from sources with a higher glycemic index and lower consumption of whole grains during puberty are prospectively associated with higher IL-6 concentrations in younger adulthood among healthy individuals. *J Nutr.* 2014;144(10):1586-93. doi:10.3945/jn.114.193391
86. Hennigar SR, McClung JP, Pasiakos SM. Nutritional interventions and the IL-6 response to exercise. *FASEB J.* 2017;31(9):3719-28. doi:10.1096/fj.201700080R
87. Gaber W, Azkalany GS, Gheita TA, Mohey A, Sabry R. Clinical significance of serum interleukin-6 and -174 G/C promoter polymorphism in rheumatoid arthritis patients. *Egypt Rheumatol.* 2013;35(2):107-13. doi:10.1016/j.ejr.2012.11.002
88. Goyenechea E, Parra D, Martínez JA. Impact of interleukin 6 -174G>C polymorphism on obesity-related metabolic disorders in people with excess in body weight. *Metabolism.* 2007;56(12):1643-8. doi:10.1016/j.metabol.2007.07.005
89. Lu YL, Yu XD. The research on serum level and polymorphism of IL-6 gene. *Chin J Cell Mole Immunol.* 2009;25:725-8. doi:10.1172/JCI2629
90. Pavkova Goldbergova M, Nemeč P, Lipkova J, Jarkovsky J, Gatterova J, Ambrozkova D, et al. Relation of IL-6, IL-13 and IL-15 gene polymorphisms to the rheumatoid factors, anti-CCP and other measures of rheumatoid arthritis activity. *Int J Immunogenet.* 2014;41(1):34-40. doi:10.1111/iji.12065
91. Wielnińska J, Dratwa M, Świerkot J, Korman L, Iwaszko M, Wysoczańska B, et al. Interleukin 6 gene polymorphism is associated with protein serum level and disease activity in Polish patients with rheumatoid arthritis. *HLA.* 2018;92 Suppl 2:38-41. doi:10.1111/tan.13355

92. Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S, et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. *J Clin Invest.* 1998;102(7):1369-76. doi:10.1172/JCI2629
93. Ferrer MD, Capó X, Martorell M, Busquets-Cortés C, Bouzas C, Carreres S, et al. Regular practice of moderate physical activity by older adults ameliorates their anti-inflammatory status. *Nutrients.* 2018;10(11):1780. doi:10.3390/nu10111780
94. Alhilali D, Mohammed S. Genetic polymorphisms at TNF-alpha receptors associated some autoimmune diseases and response of Anti-TNF biologics. *Iraqi J Pharm Sci.* 2024;33(4):49-58. doi:10.31351/vol33iss4pp49-58